Search
Pinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalIt is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders [A19697] and may be considered as effective first-lline therapy for patients with irritable … Pinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function.
Categories: Drugs for Functional Gastrointestinal DisordersRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalsafer for use in patients with contraindications to standard therapy. … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and
Fidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigational[A190486] The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.[L11575] … [A190486] The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of [vancomycin], which was the primary drug of choice for _C. difficile_ infection before
Belzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L36105] Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and inhibit these proteins. … This discovery led to the initial development of belzutifan (at the time called PT2977), which was further developed by a spin-off company named Peloton Pharmaceuticals (which itself was eventually acquired
Glycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalChemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Azelaic acid
go.drugbank.com/drugs/DB00548ApprovedInvestigationalAzelaic acid's antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis. … Azelaic acid is effective against a number of skin conditions, such as mild to moderate acne, when applied topically in a cream formulation of 20%.
Categories: Anti-Acne Preparations for Topical UseFencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnFencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. It is especially useful in patients with chronic conditions due to its favourable safety profile. … It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose.
Categories: Psychostimulants, Agents Used for ADHD and NootropicsOzanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis. … Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease.
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigationaltwo main forms of ANCA-associated vasculitis - in combination with [rituximab] or [cyclophosphamide]. … by the presence of ANCAs in the serum.
Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.